Comparison of Metoprolol and Sacubitril/Valsartan in Chinese Patients With Heart Failure: A Retrospective Cohort Study.

IF 2.4 4区医学 Q3 PHARMACOLOGY & PHARMACY

Dose-Response Pub Date : 2025-05-21 eCollection Date: 2025-04-01 DOI:10.1177/15593258251344992

Yali Huang, Qianni Lan, Yuan Liu

{"title":"Comparison of Metoprolol and Sacubitril/Valsartan in Chinese Patients With Heart Failure: A Retrospective Cohort Study.","authors":"Yali Huang, Qianni Lan, Yuan Liu","doi":"10.1177/15593258251344992","DOIUrl":null,"url":null,"abstract":"Background: Sacubitril/valsartan is recommended for patients with New York Heart Association class II to III heart failure (class 1 recommendation). The objectives of the study were to evaluate the effectiveness and safety of metoprolol against sacubitril/valsartan in patients with heart failure and reduced ejection fraction (HFrEF).Methods: In retrospective study, patients aged ≥18 years with heart failure and less than 40% of left ventricular ejection fraction received 25 mg metoprolol once daily (ML cohort, n = 117) or 50 mg sacubitril/valsartan twice daily (SV cohort, n = 128) for 6-months.Results: Systolic and diastolic blood pressures, heart rates, N-terminal pro-brain natriuretic peptide values, and left ventricular ejection fraction values improved across both cohorts, especially in the ML cohort after treatments for 6-months as compared to before treatments (P < .05 for all). Death was higher in the SV cohort than in the ML cohort over 15 months (10 (8%) vs. 2 (2%), P = .0362). Fatigue, depression, shortness of breath, and wheezing have been reported in patients in the ML cohort. Dizziness, hyperkalemia, fatigue, abdominal or stomach pain, and blurred vision have been reported in patients in the SV cohort.Conclusions: Metoprolol may offer superior safety with comparable efficacy.","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"23 2","pages":"15593258251344992"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099163/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dose-Response","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15593258251344992","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sacubitril/valsartan is recommended for patients with New York Heart Association class II to III heart failure (class 1 recommendation). The objectives of the study were to evaluate the effectiveness and safety of metoprolol against sacubitril/valsartan in patients with heart failure and reduced ejection fraction (HFrEF).

Methods: In retrospective study, patients aged ≥18 years with heart failure and less than 40% of left ventricular ejection fraction received 25 mg metoprolol once daily (ML cohort, n = 117) or 50 mg sacubitril/valsartan twice daily (SV cohort, n = 128) for 6-months.

Results: Systolic and diastolic blood pressures, heart rates, N-terminal pro-brain natriuretic peptide values, and left ventricular ejection fraction values improved across both cohorts, especially in the ML cohort after treatments for 6-months as compared to before treatments (P < .05 for all). Death was higher in the SV cohort than in the ML cohort over 15 months (10 (8%) vs. 2 (2%), P = .0362). Fatigue, depression, shortness of breath, and wheezing have been reported in patients in the ML cohort. Dizziness, hyperkalemia, fatigue, abdominal or stomach pain, and blurred vision have been reported in patients in the SV cohort.

Conclusions: Metoprolol may offer superior safety with comparable efficacy.

Abstract Image

查看原文本刊更多论文

美托洛尔与苏比里尔/缬沙坦治疗心力衰竭的回顾性队列研究

背景：苏比里尔/缬沙坦推荐用于纽约心脏协会II至III级心力衰竭患者（1级推荐）。该研究的目的是评估美托洛尔对抗苏比里尔/缬沙坦在心力衰竭和射血分数降低（HFrEF）患者中的有效性和安全性。方法：在回顾性研究中，年龄≥18岁且左心室射血分数小于40%的心力衰竭患者接受25 mg美托洛尔每日1次（ML队列，n = 117）或50 mg沙比里尔/缬沙坦每日2次（SV队列，n = 128）治疗6个月。结果：两个队列的收缩压和舒张压、心率、n端前脑利钠肽值和左心室射血分数值在治疗6个月后均有所改善，尤其是在ML队列中，与治疗前相比（P < 0.05）。15个月内，SV组的死亡率高于ML组（10人（8%）比2人（2%），P = 0.0362）。ML队列患者中有疲劳、抑郁、呼吸短促和喘息的报道。据报道，SV队列患者出现头晕、高钾血症、疲劳、腹痛或胃痛和视力模糊。结论：美托洛尔具有较好的安全性和相当的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dose-Response PHARMACOLOGY & PHARMACY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

4.90

自引率

4.00%

发文量

140

审稿时长

>12 weeks

期刊介绍： Dose-Response is an open access peer-reviewed online journal publishing original findings and commentaries on the occurrence of dose-response relationships across a broad range of disciplines. Particular interest focuses on experimental evidence providing mechanistic understanding of nonlinear dose-response relationships.